{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:30:11Z","timestamp":1740148211830,"version":"3.37.3"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T00:00:00Z","timestamp":1566345600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T00:00:00Z","timestamp":1566345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s12094-019-02201-z","type":"journal-article","created":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T12:02:47Z","timestamp":1566388967000},"page":"1754-1762","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A retrospective chart review study describing metastatic melanoma patients profile and treatment patterns in Spain"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2476-668X","authenticated-orcid":false,"given":"I.","family":"M\u00e1rquez-Rodas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Arance","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Berrocal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. L.","family":"Larios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Curto-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. X.","family":"Campos-Tapias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. B.","family":"Blanca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Martin-Algarra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,21]]},"reference":[{"key":"2201_CR1","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/CMR.0000000000000200","volume":"25","author":"R Dummer","year":"2015","unstructured":"Dummer R. Integrating first-line treatment options into clinical practice: what\u2019s new in advanced melanoma? Melanoma Res. 2015;25:461\u20139.","journal-title":"Melanoma Res"},{"key":"2201_CR2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s12094-017-1768-1","volume":"20","author":"A Berrocal","year":"2018","unstructured":"Berrocal A, Arance A, Castell\u00f3n VE, de la Cruz L, Espinosa E, Cao MG, et al. SEOM clinical guideline for the management of malignant melanoma (2017). Clin Transl Oncol. 2018;20:69\u201374.","journal-title":"Clin Transl Oncol"},{"key":"2201_CR3","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ejca.2016.05.005","volume":"63","author":"C Garbe","year":"2016","unstructured":"Garbe C. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline\u2014update 2016. Eur J Cancer. 2016;63:201\u201317.","journal-title":"Eur J Cancer."},{"key":"2201_CR4","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ejca.2017.06.028","volume":"83","author":"S Ugurel","year":"2017","unstructured":"Ugurel S. Survival of patients with advanced metastatic melanoma: the impact of novel therapies\u2014update 2017. Eur J Cancer. 2017;83:247\u201357.","journal-title":"Eur J Cancer"},{"key":"2201_CR5","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1007\/s00432-017-2453-z","volume":"143","author":"M Polkowska","year":"2017","unstructured":"Polkowska M. Survival of melanoma patients treated with novel drugs: retrospective analysis of real-world data. J Cancer Res Clin Oncol. 2017;143:2087\u201394.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2201_CR6","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s12094-013-1090-5","volume":"16","author":"S Mart\u00edn-Algarra","year":"2014","unstructured":"Mart\u00edn-Algarra S. Guidelines for biomarker testing in metastatic melanoma: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol. 2014;16:362\u201373.","journal-title":"Clin Transl Oncol"},{"key":"2201_CR7","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1157\/13090479","volume":"206","author":"JA Avil\u00e9s","year":"2006","unstructured":"Avil\u00e9s JA. Epidemiology and survival of cutaneous melanoma in Spain: a report of 552 cases (1994\u20132003). Rev Clin Esp. 2006;206:319\u201325.","journal-title":"Rev Clin Esp"},{"key":"2201_CR8","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S0001-7310(05)73105-7","volume":"96","author":"S S\u00e1enz","year":"2005","unstructured":"S\u00e1enz S. Melanoma epidemiology in Spain. Actas Dermosifiliogr. 2005;96:411\u20138.","journal-title":"Actas Dermosifiliogr."},{"key":"2201_CR9","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.ad.2013.02.003","volume":"104","author":"L R\u00edos","year":"2013","unstructured":"R\u00edos L, Nagore E, L\u00f3pez JL, Redondo P, Mart\u00ed RM, Fern\u00e1ndez-de-Misa R, et al. Melanoma characteristics at diagnosis from the Spanish national cutaneous melanoma registry: 15 years of experience. Actas Dermosifiliogr. 2013;104:789\u201399.","journal-title":"Actas Dermosifiliogr."},{"key":"2201_CR10","doi-asserted-by":"crossref","unstructured":"Mohr PM, Ascierto P, Arance A, McArthur G, Hernaez A, Kaskel P, et al. Real-world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab. J Eur Acad Dermatol Venereol. 2017;71(5).","DOI":"10.1111\/jdv.14633"},{"key":"2201_CR11","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ejca.2016.11.021","volume":"72","author":"A Jochems","year":"2017","unstructured":"Jochems A, Schouwenburg MG, Leeneman B, Franken G, van den Eertwegh AJ, Haanen JB, et al. Dutch Melanoma Treatment Registry: quality assurance in the care of patients with metastatic melanoma in the Netherlands. Eur J Cancer. 2017;72:156\u201365.","journal-title":"Eur J Cancer"},{"key":"2201_CR12","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S0001-7310(09)72550-5","volume":"100","author":"D Moreno-Ram\u00edrez","year":"2009","unstructured":"Moreno-Ram\u00edrez D, de la Cruz L, Ferr\u00e1ndiz L, Camacho FM. Study and treatment of locally advanced melanoma. Actas Dermosifiliogr. 2009;100:767\u201379.","journal-title":"Actas Dermosifiliogr."},{"key":"2201_CR13","doi-asserted-by":"crossref","unstructured":"Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Keilholz U on behalf of the ESMO Guidelines Committee. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 5:v126\u2013132.","DOI":"10.1093\/annonc\/mdv297"},{"key":"2201_CR14","unstructured":"European Medicines Agency. EPAR summary for the public. 2012. \nhttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR__Summary_for_the_public\/human\/002409\/WC500124320.pdf\n\n."},{"key":"2201_CR15","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Informe de Posicionamiento terapeutico. PT\/V1\/15112013,2. Informe de Posicionamiento Terap\u00e9utico de Vemurafenib (Zelboraf\u00ae). \nhttps:\/\/www.aemps.gob.es\/medicamentosUsoHumano\/informesPublicos\/docs\/IPT-zelboraf-melanoma.pdf\n\n."},{"key":"2201_CR16","doi-asserted-by":"publisher","first-page":"269","DOI":"10.21037\/atm.2016.06.32","volume":"4","author":"P Diamantopoulos","year":"2016","unstructured":"Diamantopoulos P, Gogas H. Melanoma immunotherapy dominates the field. Ann Transl Med. 2016;4:269.","journal-title":"Ann Transl Med."},{"key":"2201_CR17","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.ctrv.2013.06.004","volume":"39","author":"J Murrell","year":"2013","unstructured":"Murrell J, Board R. The use of systemic therapies for the treatment of brain metastases in metastatic melanoma: opportunities and unanswered questions. Cancer Treat Rev. 2013;39:833\u20138.","journal-title":"Cancer Treat Rev"},{"key":"2201_CR18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ejca.2016.01.011","volume":"60","author":"M Harries","year":"2016","unstructured":"Harries M, Malvehy J, Lebbe C, Heron L, Amelio J, Szabo Z, et al. Treatment patterns of advanced malignant melanoma (stage III\u2013IV)\u2014a review of current standards in Europe. Eur J Cancer. 2016;60:179\u201389.","journal-title":"Eur J Cancer"},{"key":"2201_CR19","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","volume":"36","author":"J Chesney","year":"2018","unstructured":"Chesney J, Puzanov I, Collichio F, Singh P, Milhem MM, Glaspy J. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. JCO. 2018;36:1658\u201367.","journal-title":"JCO."},{"key":"2201_CR20","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s12094-016-1535-8","volume":"19","author":"J Salvador","year":"2017","unstructured":"Salvador J, Urtasun JA, Duart FJB, Garc\u00eda-Campelo R, Carbonero RG, Lianes P, et al. Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions. Clin Transl Oncol. 2017;19:341\u201356.","journal-title":"Clin Transl Oncol"},{"key":"2201_CR21","unstructured":"A. Percentage of patients treated under available therapies or within a clinical trial (RCT) according to stage first-treatment line treatment for advanced melanoma (real clinical practice or as part of a RCT) from 2007 to 2015."}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-019-02201-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-019-02201-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-019-02201-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T23:18:26Z","timestamp":1597879106000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-019-02201-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,21]]},"references-count":21,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["2201"],"URL":"https:\/\/doi.org\/10.1007\/s12094-019-02201-z","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"type":"print","value":"1699-048X"},{"type":"electronic","value":"1699-3055"}],"subject":[],"published":{"date-parts":[[2019,8,21]]},"assertion":[{"value":"3 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Iv\u00e1n M\u00e1rquez Rodas has participated in consulting and advisory boards of BMS, MSD, Novartis, Roche, Pierre-Fabre, Amgen, AstraZeneca, Merck-Serono, Incyte, Bioncotech, and Sanofi. Ana Arance has participated in consulting, advisory boards and Speaker\u2019s bureau of BMS, Roche, MSD and Novartis. Alfonso Berrocal has received honoraria for consulting and advisory boards of MSD, BMS, Roche and Novartis. Cindy L. Larios and Jordi Curto are employed by MFAR Clinical Research, a CRO for Amgen for this study, analysis and manuscript. Ignasi X. Campos Tapias and Ana Bel\u00e9n Blanca are full-time employees at Amgen S.A. and own Amgen stocks. Salvador Mart\u00edn Algarra reports receiving advisory board fees from Amgen, BMS, Incyte, Merck-Serono, MSD, Pierre-Fabre, Tesaro and Roche; speaker activities fees from BMS, MSD and Pierre-Fabre; consulting fees from Novartis and travel support from Roche.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by an independent Ethical Committee and conducted in accordance with the good clinical practice (GCP), the principles of the Declaration of Helsinki and current local applicable regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients participating in the study signed informed consent.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}